Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) had its price target lowered by equities research analysts at Canaccord Genuity Group from $13.00 to $12.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. Canaccord Genuity Group's price target points to a potential upside of 243.35% from the stock's previous close.
Other research analysts have also issued reports about the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Aclaris Therapeutics in a research note on Monday, September 21st. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Aclaris Therapeutics in a report on Wednesday, October 28th. Wedbush downgraded shares of Aclaris Therapeutics from an "outperform" rating to a "neutral" rating and decreased their target price for the stock from $8.00 to $3.00 in a research note on Tuesday. Wall Street Zen raised Aclaris Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, October 24th. Finally, Craig Hallum set a $9.00 price target on Aclaris Therapeutics in a research report on Wednesday, October 28th. Three research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $10.67.
View Our Latest Stock Analysis on ACRS
Aclaris Therapeutics Price Performance
Shares of ACRS traded down $0.12 during mid-day trading on Tuesday, reaching $3.50. 734,260 shares of the company's stock were exchanged, compared to its average volume of 2,245,146. The stock has a market capitalization of $554.35 million, a PE ratio of -6.06 and a beta of 0.96. The business's fifty day simple moving average is $4.38 and its 200-day simple moving average is $4.53. Aclaris Therapeutics has a 52-week low of $2.34 and a 52-week high of $6.60.
Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.04. The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.27 million. Aclaris Therapeutics had a negative net margin of 1,244.09% and a negative return on equity of 59.19%. Equities research analysts predict that Aclaris Therapeutics will post -0.56 earnings per share for the current year.
Hedge Funds Weigh In On Aclaris Therapeutics
Several institutional investors have recently bought and sold shares of ACRS. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Aclaris Therapeutics in the 3rd quarter worth $40,000. MBE Wealth Management LLC acquired a new position in shares of Aclaris Therapeutics during the third quarter worth about $53,000. Jefferies Financial Group Inc. acquired a new position in shares of Aclaris Therapeutics during the second quarter worth about $58,000. Legal & General Group Plc acquired a new position in shares of Aclaris Therapeutics during the second quarter worth about $61,000. Finally, Walleye Capital LLC purchased a new position in Aclaris Therapeutics during the second quarter worth about $104,000. 98.34% of the stock is owned by institutional investors and hedge funds.
Aclaris Therapeutics News Summary
Here's some of the latest news about ACRS:
- Positive Sentiment: Aclaris began a Phase 2b trial of modzatinib for moderate-to-severe lichen planus, a condition with no FDA-approved treatments. The drug has FDA Fast Track designation, and initial results from the oral-disease cohort are expected in the second half of 2027. Aclaris initiates Phase 2b modzatinib trial
- Neutral Sentiment: The company says it will prioritize its oral kinase inhibitors and ATI-052, including a planned Phase 2b trial of ATI-052 in eosinophilic esophagitis in early 2027. These programs provide potential future catalysts, though they remain in development. Aclaris reports Phase 2 bosakitug results
- Negative Sentiment: Wedbush cut its rating from Outperform to Neutral and reduced its price target from $8 to $3, signaling a less favorable outlook. Wedbush downgrade report
About Aclaris Therapeutics
(
Get Free Report)
Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company's development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aclaris Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.
While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.